Amylyx Pharmaceuticals, Inc.

NASDAQ:AMLX

Biotechnology

Healthcare
$26.20 +0.93%

+$0.14 today

Market cap
$3.37B
Beta
-0.16
P/E (TTM)
-11.3
EPS (TTM)
-$1.36
52W Low $4.80High $18.61

Volume 1.76M

Average 1.21M

Balance Sheet

Inspect the capital base behind the business.

Assets

$332.64M

FY 2025 · Annual

+71.8% YoY

Liabilities

$27.39M

FY 2025 · Annual

-5.1% YoY

Equity

$305.26M

FY 2025 · Annual

+85.3% YoY

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents50.19M62.53M170.2M77.39M226.65M
Short-term Investments45.93M284.42M201.16M99.11M90.33M
Net Receivables015.31M40.05M447K88K
Inventory09.77M38.32M00
Other Current Assets3.44M10.11M14.93M12.48M6.6M
Total Current Assets104.95M382.13M464.67M189.43M323.67M
Property, Plant & Equipment (Net)474K8.14M6.41M2.73M5.49M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets189K1.19M46.38M1.47M3.48M
Total Non-current Assets663K9.32M52.79M4.2M8.97M
Total Assets105.61M391.45M517.45M193.63M332.65M
Account Payables4.37M6.26M22.06M2.94M3.52M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities4.28M15.23M40.93M9.99M10.06M
Total Current Liabilities17.4M46.61M82.04M28.41M22.69M
Long-term Debt00004.7M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities239.39M0000
Total Non-current Liabilities239.39M4.24M1.98M463K4.7M
Total Liabilities256.78M50.85M84.02M28.87M27.39M
Common Stock1K7K7K7K11K
Retained Earnings(155.85M)(354.22M)(304.95M)(606.69M)(751.43M)
Accumulated OCI9K(86K)197K(92K)404K
Other Stockholders Equity00000
Minority Interest00000
Total Equity(151.17M)340.61M433.43M164.77M305.26M
Total Debt06.28M4.24M1.98M5.96M
Net Debt(50.19M)(56.25M)(165.96M)(75.41M)(220.69M)

Balance Sheet

Assets, liabilities & equity

Cash & Equivalents$240.1M
Short-term Investments$528.0M
Receivables$2.9M
Other Current$7.8M
Total Current Assets$778.9M
PP&E (Net)$4.4M
Other Non-current$3.5M
Total Non-current Assets$7.9M
Total Assets$786.8M

Analysis

Selected assets total $786.8M for Latest. The largest visible component is Short-term Investments at $528.0M, about 67.1% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipNov 12, 2026
4Statement of changes in beneficial ownershipNov 12, 2026
4Statement of changes in beneficial ownershipNov 12, 2026
10-QQuarterly reportNov 5, 2026
8-KCurrent reportNov 5, 2026

How much cash does AMLX have?

Amylyx Pharmaceuticals, Inc. (AMLX) reported $226.65M in cash and equivalents in fiscal 2025.

How much debt does AMLX carry?

Amylyx Pharmaceuticals, Inc. (AMLX) reported $5.96M of total debt, with net debt of -$220.69M.